News

RV Damage on MRI Linked to Heart Events in Cardiac Sarcoidosis

Findings of defects in the heart’s right ventricle, as assessed with an MRI scan, can predict the occurrence of cardiovascular events in people with confirmed or suspected cardiac sarcoidosis, a review study showed. Particularly, scarring in the right ventricle muscle was a “strong independent predictor” of sudden heart-related death,…

Efzofitimod Earns Orphan Drug Status for Sarcoidosis in Europe

The European Commission (EC) has granted orphan drug designation to aTyr Pharma’s lead therapeutic candidate efzofitimod for treating sarcoidosis. Orphan drug status is granted to investigational therapies that show significant potential for treating chronic or life-threatening disease that affect no more than five in 10,000 people in the…

Worse Lung Function Prevalent in Disadvantaged Neighborhoods

People with sarcoidosis who live in neighborhoods lacking economic and social resources have lower lung function and faster lung function decline, a study in the U.S. and Canada revealed. Non-white patients were overrepresented in the group with greater disadvantage, suggesting how race and differences in socioeconomic status can lead…

First Patient Dosed in Phase 2 Trial of Namilumab

The first participant has been dosed in a Phase 2 clinical trial testing the experimental therapy namilumab in people with pulmonary sarcoidosis, the therapy’s developer Kinevant Sciences announced. “We are excited to advance namilumab as a promising new treatment for pulmonary sarcoidosis since it has a mechanism of…